IL37 and rheumatoid arthritis: Recent studies on IL-23 focus on the risk of autoimmune inflammation diseases, including rheumatoid arthritis (RA) and psoriasis, considerably improving not only the understanding of molecular pathogenesis but also the development of potential therapeutic targets17, 18, 19.